Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

NEWTON, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Bank of America CNS Therapeutics Virtual Conference on Monday, Oct. 7, 2024, at 8:00 a.m. ET.

Read more at globenewswire.com